Insight & Intelligence

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

January 15, 2012 (Vol. 32, No. 2)

U.K. Works to Keep Its Edge

  • 2011 was a tough year for the U.K.’s biotech industry, especially with several big pharma closures. The good news is that there is new growth in development and manufacturing of biotherapeutics. Pfizer and Novartis may have shut down their U.K. sites, but as the saying goes, when one ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.

Be sure to take the GEN Poll

{{ vm.poll.Title }}

More »